Annual General Meeting – Meeting Materials
July 6, 2020
The Annual General Meeting (AGM) of Imagion Biosystems Limited (the Company) will be held virtually on Wednesday, 22 July 2020 at 11.00am (Melbourne time). In
Category: Investor updates
Imagion Biosystems Market Herald Interview
July 3, 2020
We recently announced plans to conduct our first in-human study for MagSense in Australia later this year. In this Market Herald interview, watch IBX CEO Bob
Appendix 3Y — Change in Director’s Interest Notice
June 26, 2020
Imagion Biosystems has made the attached Appendix 3Y announcements in relation to change of Directors interest notice. Read Appendix 3Y — Change in Director’s Interest
First in-human study update – webcast presentation
June 24, 2020
You can also register to watch the entire Zoom webcast on-demand by clicking here
Appendix 2A — Vesting of Performance Rights
June 23, 2020
Imagion Biosystems Limited advises that the 200,000 Performance Rights issued to Directors of the Company under the Company Long-term Incentive Plan on 14 June 2018,
Investor Webcast Presentation
June 23, 2020
Imagion Biosystems has released an investor webcast presentation announcement to the market. View the webcast presentation.
Imagion announces plan to undertake first clinical study in Australia
June 22, 2020
Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce its plans to conduct
Notice of Annual General Meeting and Explanatory Memorandum
June 19, 2020
TAKE NOTICE that the Annual General Meeting of Shareholders of the Company will be held at the time, date and place specified below: Time: 11.00 am
Market Herald Interview
June 3, 2020
In May, Imagion signed a collaboration agreement with Siemens Healthineers to explore the utility of our MagSense nanoparticles as a contrast agent in MRI scanning.
Imagion Nanoparticle Manufacturing Update
May 26, 2020
Imagion Biosystems Limited is pleased to report that the first phase of manufacturing of the MagSense® HER2 nanoparticle formulation under Good Manufacturing Practice (GMP) conditions